Cost-effectiveness of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease in the UK.pptx (254.64 kB)

Cost-effectiveness of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease in the UK (2012)

Download (254.64 kB)
poster
posted on 28.02.2020, 11:41 by Yang Meng, Hazel Squires, John Stevens, Emma Simpson, Steve Thomas, Jonathan Michaels, Gerard Stansby, Mark O'Donnell

The study aims to assess the cost-effectiveness of the vasoactive drugs cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for intermittent claudication due to peripheral arterial disease (PAD) in adults whose symptoms continue despite a period of conservative management.


History

Ethics

The project has ethical approval and have included the number in the description field

Policy

The data complies with the institution and funders' policies on access and sharing

Sharing and access restrictions

The data can be shared openly

Data description

  • The file formats are open or commonly used

Methodology, headings and units

  • Headings and units are explained in the files

Licence

Exports

Logo branding

Licence

Exports